Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O95568
UPID:
MET18_HUMAN
Alternative names:
Arsenic-transactivated protein 2; Methyltransferase-like protein 18
Alternative UPACC:
O95568; B2R9T5
Background:
Histidine protein methyltransferase 1 homolog, also known as Arsenic-transactivated protein 2 and Methyltransferase-like protein 18, plays a crucial role in protein synthesis. It specifically monomethylates RPL3, a process vital for regulating translation elongation. This modification on RPL3 histidine slows ribosome traversal on tyrosine codons, ensuring adequate time for protein folding and preventing aggregation of tyrosine-rich proteins.
Therapeutic significance:
Understanding the role of Histidine protein methyltransferase 1 homolog could open doors to potential therapeutic strategies. Its unique function in protein synthesis regulation highlights its potential as a target for developing treatments aimed at preventing protein misfolding and aggregation, common features in numerous diseases.